Technology

A5 Biotech Corp

We are a specialty biotechnology company engaged in the development and marketing of novel immun therapeutic applications of a natural Gamma – Interferon (nG-IFN)

Such applications include the diagnostic, the prevention and the treatment of various animal and human diseases.

The pathologies targeted by Cytokines Biotech’s nG-INF include viral, bacterial, fungal and parasitic infections as well as various auto-immune conditions and cancer, and emphasis will be initially put on opportunistic infections in HIV patients, antibiotic-resistant bacteria and some rare types of cancers.

What does this mean for future of A5 Laboratories?

By engaged in the development and marketing of novel immun therapeutic applications, A5 can become a fully integrated global biopharmaceutical company by conducting internal late stage development, registration and commercialization of naturrrally produced interferon products using our novel production technology.

Step 1: production of interferon for the treatment of diseases in veterinary applications.

Step 2: Submission and approval of interferon for the treatment of diseases in humans.

Did you know…

Several different types of interferon are now approved for use in humans. By March 10, 2009, MultiferonTM — known generically as human leukocyte interferon-alpha (HuIFN-alpha-Le) — was being used in 14 European countries. This drug was approved for treatment of patients with high risk (stage IIb-III)cutaneous melanoma, after 2 treatment cycles with dacarbazine, following a clinical trial performed in Germany. [1][2][3]

• [1] http://en.wikipedia.org/wiki/Melanoma#Staging
• [2] Läkemedelsverke: http 3 milj IE solu f inj pre-filled syringe ENG
• [3] Stadler, R., et al. “Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial”. Acta Oncologica, Volume 45, Issue 4 June 2006, pages 389–399.